Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

Notes

• Note

• Anticipate appraisal will begin late December 2026

• Timelines for this appraisal will be available in due course